tbuckley/cabot-search huggingface dataset:
364P Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Authors: A.R. Ahmad, L.M. Tho, Y.K.J. Chik, W.C.K. Lee, T-Y. Yang, X. Le, A.K. Eisert, U. Himpe, C. De Bondt, J. Mazieres, I. Petrini, W-S. Lam, K. Joshi, K. Berghoff, S. Vlassak, N. Karachaliou, A.J. Van Der Wekken, T-C. Hsia
Journal: Annals of Oncology (2022)
247TiP Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
Authors: V.H.F. Lee, D.L.W. Kwong, A.S.Y. Chan, C.C. Tong, R. Tsang, C.K. Chung
Journal: Annals of Oncology (2022)
276MO Superior single agent effectiveness with plinabulin (Plin) versus (vs) placebo (Plac) for docetaxel (Doc)-induced neutropenia (DIN) prevention in non-small cell lung cancer (NSCLC) patients (pts)
Authors: D. Blayney, L. Huang, S. Ogenstad, G. Legaspi, S. Duprez, R. Mohanlal
Journal: Annals of Oncology (2022)
321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION
Authors: J.C-H. Yang, T. Kato, M-J. Ahn, H. Sakai, M. Morise, Y-M. Chen, J-Y. Han, J. Yang, J. Zhao, J.L-C. Huang, K. Berghoff, R. Bruns, H. Vioix, G.P. Otto, X. Le, P.K. Paik
Journal: Annals of Oncology (2022)
LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)
Authors: Y. Cheng, L. Han, L. Wu, J. Chen, H. Sun, G. Wen, Y. Ji, M. Dvorkin, J. Shi, Z. Pan, J. Shi, X. Wang, Y. Bai, T. Melkadze, Y. Pan, X. Min, M. Viguro, W. Kang, Q. Wang, J. Zhu
Journal: Annals of Oncology (2022)
67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Authors: S.L. Chan, M. Kudo, B. Sangro, R.K. Kelley, J. Furuse, J-W. Park, P. Sunpaweravong, A. Fasolo, T. Yau, T. Kawaoka, A-L. Cheng, S. Azevedo, M.E. Reig Monzon, E. Assenat, M. Yarchoan, A.R. He, M. Makowsky, C. Gupta, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2022)
102P A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Authors: C. Nie, H. Lv, B. Chen, W. Xu, J. Wang, S. Wang, Y. Liu, Y. He, J. Zhao, X. Chen
Journal: Annals of Oncology (2022)
328P Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407
Authors: Y. Cheng, L. Zhang, J. Hu, D. Wang, C.P. Hu, J. Zhou, L. Wu, L. Cao, J. Liu, H. Zhang, H. Sun, Z. Wang, H. Gao, Y. Sun, X. Hu, E. Jensen, P.O. Schwarzenberger, L. Paz-Ares
Journal: Annals of Oncology (2022)
127P LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Authors: J. Wonglhow, P. Sunpaweravong, C. Sathitruangsak, S. Lucien Geater, A. Dechaphunkul
Journal: Annals of Oncology (2022)
32P Tumor growth inhibition effect of PLAG by regulation of neutrophil infiltration in ICI insensitivity B16F10 melanoma
Authors: G.T. Kim, E.Y. Kim, S-H. Shin, H. Lee, S.H. Lee, J.S. Lee, J.W. Choi, K-Y. Sohn, J.W. Kim
Journal: Annals of Oncology (2022)
222O Updated efficacy and safety of larotrectinib in patients with TRK fusion salivary gland tumours
Authors: L. Shen, D.S. Hong, M. Tahara, C.S. Baik, J.R. Bauman, J. Gilbert, M.S. Brose, J.E. Grilley-Olson, T. Patil, R.S. McDermott, L.E. Raez, J.M. Johnson, R. Norenberg, L. Dima, C.E. Mussi, X. Le, A. Drilon
Journal: Annals of Oncology (2022)
55P Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Authors: A. Kefayat, M. Mirzadeh, F. Molaabasi, S.A. Poursamar, F. Ghahremani, M. Rafienia, N. Arbab Jolfaie
Journal: Annals of Oncology (2022)
202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor
Authors: J. Wang, Y. Shen, J. Chen, X. Chen, Q. Guan, Q. Liu, J. Xu, Y. Xu, B. Zhang, H. Zhang, Y. Zhu, Y. Zhang
Journal: Annals of Oncology (2022)
318P EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Authors: M. Gogishvili, T. Melkadze, T. Makharadze, D. Giorgadze, M. Dvorkin, K.D. Penkov, K. Laktionov, G. Nemsadze, M. Nechaeva, I. Rozhkova, E. Kalinka, C. Gessner, B. Moreno Jaime, R. Passalacqua, S. Li, K. McGuire, R.G. Quek, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2022)
400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Authors: O. Hamid, A. Weise, T.M. Kim, M. Mckean, N. Lakhani, J. Crown, J. Kaczmar, K. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, G. Gullo
Journal: Annals of Oncology (2022)
224O Survival differences between EU and Asia for head and neck cancer: Results of the RARECAREnet-Asia collaboration
Authors: A. Trama, T. Matsuda, H. Charvat, R.R.C-J. Chiang, A.J. van Gestel, F. Martin, G. Geleijnse, S. Bonfarnuzzo, L.F. Licitra, S. Cavalieri, C. Resteghini, G. Gatta, L. Botta
Journal: Annals of Oncology (2022)
309P Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Authors: S. Murata, H. Horinouchi, M. Morishita, S. Kaku, Y. Shinno, Y. Okuma, T. Yoshida, Y. Goto, N. Yamamoto, K. Okuma, M. Kusumoto, Y. Ohe
Journal: Annals of Oncology (2022)
36P Preclinical evaluation of novel MCL-1 degrader in in vitro and in vivo cancer models
Authors: P. Kowalczyk, T. Tomczyk, J. Arenciba, M. Milewicz, J. Skalska, D. Trębicka, K. Poniatowska, J. Adamczyk, K. Wójcik, S. Cottens, P. Dobrzański, M. Biśta, K. Brach, M. Drewniak-Świtalska, A. Tracz, M. Pastok, K. Górecka, K. Chrzanowska, K. Kaczanowska, M. Walczak
Journal: Annals of Oncology (2022)
147P Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Authors: J. Molina Cerrillo, I. Ortego, A. Pinto Marin, T. Alonso Gordoa, J. Puente, J.A. Arranz Arija, M.P. Lopez Criado, A. Gonzalez Morales, N. Vidal Cassinello, D.E. Castellano Gauna, E. Sevillano Fernandez, J. Garcia Donas, E. Grande Pulido
Journal: Annals of Oncology (2022)
447P Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Authors: H. Kameoka, J. Tauchi, K. Koshiba, M. Uoi, D. Hisamatsu, A. Miyada, S. Takada, T. Hiromasa, R. Matsui, K. Ohashi, T. Kawasaki
Journal: Annals of Oncology (2022)
70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Authors: K. Kato, H. Yoon, E. Raymond, R. Hubner, Y. Shu, Y. Pan, S.R. Park, L. Ping, Y. Jiang, J. Zhang, X. Wu, Y. Yao, L. Shen, T. Kojima, C-Y. Lin, L. Wang, A. Tao, Y. Peng, L. Li, J. Xu
Journal: Annals of Oncology (2022)
193P Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Authors: A.V. Sultanbaev, K. Menshikov, S. Musin, N. Sultanbaeva, A. Nasretdinov, I. Menshikova, A. Fatikhova
Journal: Annals of Oncology (2022)
56P Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Authors: S.S. Panda, A. Sehrawat, S. Kayal, D. Sundriyal, M. Khanna, A. Philips, D. Jain, L. Moharana, K. Tiwari, D. Kaaviya, S. Cyriac, A. Jose, S.V. Saju, K.K. Rathnam, P. Ganesan
Journal: Annals of Oncology (2022)
294P Cross-sectional analysis on cancer-related distress, belief in alternative medicine among cancer patients and attendants visiting a tertiary care center in Northern India
Authors: A. Sehrawat, S. Malik, P. Bhardwaj, M.C. Muddabhaktuni, E. Chowdhury, N. Perween, S. Tyagi, R. Joshi, L. Chadha, G. Dhingra, D. Ram, P. Dhamija, M. Gupta, D. Sundriyal
Journal: Annals of Oncology (2022)
327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial
Authors: G.F. Ho, M. Ozguroglu, S. Kilickap, A. Sezer, M. Gumus, I. Bondarenko, M. Gogishvili, M. Nechaeva, M. Schenker, I. Cicin, Y. Kulyaba, M. Dvorkin, K. Zyuhal, R.I. Scheusan, S. Li, J-F. Pouliot, F. Seebach, I. Lowy, G. Gullo, P. Rietschel
Journal: Annals of Oncology (2022)
46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer
Authors: T. Yoshino, N.A. Dasari, S. Lonardi, R. Garcia-Carbonero, M.E. Elez Fernandez, A. Sobrero, J.C. Yao, P. García Alfonso, J. Kocsis, A. Cubillo Gracian, A. Sartore Bianchi, V. Randrian, J. Tomasek, G. Chong, Z. Yang, W. Schelman, M. Kania, J. Tabernero, C. Eng, T. Satoh
Journal: Annals of Oncology (2022)
73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
Authors: Y.J. Kim, M. Kurosaki, K. Numata, H.Y. Lim, M. Ikeda, M. Kudo, Y-H. Huang, G. Shao, N. Kato, D-Y. Kim, S-B. Cho, C-H. Hsu, S-M. Lin, L-B. Jeng, K-K. Kuo, Y. Mao, B. Chewaskulyong, J. Khan, K. Ozgurdal, S. Qin
Journal: Annals of Oncology (2022)
365P Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Authors: A. Schuler, J. Huser, S. Schaer, S. Schmid, A. Scherz, O. Gautschi, L.A. Mauti, T. Von Briel, C. Waibel, L. Wannesson De Nicola, J. Pankovics, M.T. Mark, S.I. Rothschild, A. Addeo, W-D. Janthur, M. Siano, C. Britschgi, M. Frueh
Journal: Annals of Oncology (2022)
266P Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Authors: X. Zhang, Y-L. Wu, Y. Chen, H. Zhang, G. Wu, Y. Lu, Z. Liang, Y. Hu, Y. Cheng, J. Wang, J. Ying, W. Liu, Z. Liang
Journal: Annals of Oncology (2022)
84P Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Authors: M. Rimini, A. Casadei-Gardini, T. Tada, G. Suda, S. Shimose, M. Kudo, J. Cheon, F. Finkelmeier, H.Y. Lim, L. Rimassa, J. Presa, G. Masi, C. Yoo, S. Lonardi, F. Tovoli, S. Cascinu, A. Cucchetti
Journal: Annals of Oncology (2022)
LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
Authors: T. John, C. Grohe, J. Goldman, F. De Marinis, T. Kato, Q. Wang, J-H. Choi, B. Melotti, M. Fidler, L. Sainsbury, M. Stachowiak, S. Taggart, Y-L. Wu, M. Tsuboi, R.S. Herbst, M. Majem Tarruella
Journal: Annals of Oncology (2022)
97P BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Authors: N-J. Chiang, Y-P. Hung, M-Y. Lien, S.Y. Wu, W-L. Chang, L-Y. Bai, C-F. Hsiao, S-H. Chen, I-C. Wu, M-H. Chen
Journal: Annals of Oncology (2022)
256MO Decoding the cryptic stroma: Molecular cancer associated fibroblast 1 &amp; 4 imaging allied with mesenchymal stroma to tumor content as a radiation dose bio-predictive signature to augur the future in locally advanced esophageal cancer
Authors: K. Sekar, G. Lohith, B. Ajaikumar, V. Ramaswami, K. Kallur, S. Swamy
Journal: Annals of Oncology (2022)
80P RATIONALE-302: Tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients
Authors: S-B. Kim, E. Van Cutsem, J.A. Ajani, L. Shen, G. Barnes, N. Ding, A. Tao, T. Xia, L. Zhan, K. Kato
Journal: Annals of Oncology (2022)
178O Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENA–MONO study
Authors: K. Fujiwara, R. Kristeleit, S. Ghamande, M-C. Lim, C. Parkinson, M. Morgan, M.K. Wilson, A. Oaknin, J. Buscema, P. Bessette, D. Lorusso, F. Ueland, T. Safra, J.N. Barlin, F. Marmé, T.J. Herzog, I.A. McNeish, S. Goble, S. Hume, B.J. Monk
Journal: Annals of Oncology (2022)
69O First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study
Authors: J. Huang, Y. Song, X. Kou, Z. Tan, S. Zhang, M. Sun, J. Zhou, M. Fan, M. Zhang, Y. Song, S. Li, Y. Yuan, W. Zhuang, J. Zhang, L. Zhang, H. Jiang, K. Gu, H. Ye, Q. Wang, J. Zhu
Journal: Annals of Oncology (2022)
194P A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Authors: A. Chowdhury, D.P. Devnath, R.K. Bhowmick, A. Hoque, M.S.U. Matin, D.I.U. Rahim, T. Ahmed
Journal: Annals of Oncology (2022)
95P Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Authors: Y. Inaba, K. Ueshima, T. Ishikawa, I. Saeki, N. Morimoto, H. Aikata, N. Tanabe, Y. Wada, Y. Kondo, M. Tsuda, K. Nakao, M. Ikeda, M. Moriguchi, T. Ito, T. Hosaka, H. Koga, K. Hino, Y. Kawamura, K. Yoshimura, M. Kudo
Journal: Annals of Oncology (2022)
261MO Real-world data on prevalence of MSI-H/dMMR across 6 solid tumor types in Asia
Authors: D.S.S.P. Tan, Y.M. Kim, M-C. Lim, M. Sho, C-H. Lu, S. Nagao, S. Kubo, B-G. Kim, L-T. Chen, M. Kanai, P-H. Wang, S.Y. Rha, R. Ramar, M. Wong, T. Sasaki
Journal: Annals of Oncology (2022)
285P Reticulocyte hemoglobin equivalent as an early predictor of iron deficiency anemia in cancer patients
Authors: A. Sarin, A. Agarwal, C. Dodagoudar, S. Baghmar, S. Qureshi, A. Raj, N.S. Kailey, N.R. Hasthavaram, R. Kumar, L. Potsangbam, R. Bansal, S. Bhardwaj, S. Rajpurohit, V. Vaibhav, A. Handoo, T. Dadu, A. Mittal, N. Gupta, S. Aggarwal
Journal: Annals of Oncology (2022)
2MO Final analysis of the phase III randomized clinical trial, comparing HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting
Authors: X. Pivot, A. Manikhas, V. Shamrai, G. Dzagnidze, H.H.F. Soo, V. Kaewkangsadan, F. Petrelli, C. Villanueva, J. Kim, S. Pradhan, L. Jaison, P. Feyaerts, L. Kaufman, M-P. Derde, F. Deforce, D. Cox
Journal: Annals of Oncology (2022)
289P Cancer cachexia following breast cancer (BC) chemotherapy was associated with clinical stage, number of chemotherapy cycles, and vitamin D concentration
Authors: S.H. Hutajulu, S. Aresy, J.A. Wiranata, Y.K. Astari, H. Puspitaningtyas, D.C. Sulistyoningrum, K.T-H.W. Kartika Taroeno-Hariadi, J. Kurnianda, I. Purwanto, M.S. Hardianti
Journal: Annals of Oncology (2022)
LBA1 A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment
Authors: S. Chan, B-Y. Ryoo, F. Mo, J. Cheon, L. Li, K.H. Wong, Y. Nicole, H. Kim, C. Yoo
Journal: Annals of Oncology (2022)
393MO Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer
Authors: R. Stahel, L. Mery, A. Bardot, R. Kanesvaran, T.C. Keong, D. Pongnikorn, N. Prasongsook, S.H. Hutajulu, C. Irawan, A. Ab Manan, M. Thiagarajan, P. Sripan, S. Peters, H.H. Storm, F. Bray, R.A. Soo
Journal: Annals of Oncology (2022)
160MO Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC)
Authors: Y.Y. Zhong, A. Anton, O. Xie, N. Tan, S. Maleki, P. Parente, L. Spain, P. Gibbs, B. Tran
Journal: Annals of Oncology (2022)
85P Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
Authors: M. Ikeda, N. Kato, T. Kagawa, T. Yamashita, M. Moriguchi, S. Nakamura, K. Sawada, H. Iijima, T. Kamoshida, K. Nakao, K. Ohkawa, R. Sugimoto, T. Takehara, M. Harada, Y. Yamamoto, T. Ito, M. Kudo, N. Kokudo, K. Yamamoto, J. Furuse
Journal: Annals of Oncology (2022)
272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: Experience from a tertiary cancer center in eastern part of India
Authors: T. Chawla, J. Ghosh, S. Ganguly, B. Biswas, N. Arora, S. Vinarkar, A. Patra, A. Jha, D. Mishra, M.K. Mallath
Journal: Annals of Oncology (2022)
239P Prospective evaluation of difference in patient-reported swallowing outcomes and quality of life of tongue vs bucco-alveolar complex cancers treated with ablative surgery
Authors: A. Thaduri, M. Malhotra, P.K. Garg, D. Ram, M.P. Singh, D. Dungala, P. Kaul, A. Panuganti, K. Majumdar, S. Usmani, V. Kailey
Journal: Annals of Oncology (2022)
152P An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Authors: L. Zhou, T. Dai, D. Zhang, H. Guo, F. Zhou, B. Shi, S. Wang, Z. Ji, C. Wang, X. Yao, Q. Wei, N. Chen, J. Xing, J. Yang, C. Kong, J. Huang, D. Ye
Journal: Annals of Oncology (2022)
83P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Authors: S.L. Chan, M. Kudo, B. Sangro, R.K. Kelley, J. Furuse, J-W. Park, P. Sunpaweravong, A. Fasolo, T. Yau, T. Kawaoka, A-L. Cheng, S. Azevedo, M.E. Reig Monzon, E. Assenat, M. Yarchoan, A.R. He, M. Makowsky, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2022)
21MO Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- &amp; postmenopausal Chinese women with HR+/HER2– ABC
Authors: Z. Shao, Q. Liu, Z. Tong, W. Li, L. Cai, Y. Bai, K. Amin, P. Deshpande, Y. Bi, B. Xu
Journal: Annals of Oncology (2022)
Machine Learning Modeling of Protein-Intrinsic Features Predicts Tractability of Targeted Protein Degradation
Authors: Wubing Zhang, Shourya S. Roy Burman, Jiaye Chen, Katherine A. Donovan, Yang Cao, Chelsea Shu, Boning Zhang, Zexian Zeng, Shengqing Gu, Yi Zhang, Dian Li, Eric S. Fischer, Collin Tokheim, X. Shirley Liu
Journal: Genomics Proteomics & Bioinformatics (2022)

Abstract Targeted protein degradation (TPD) has rapidly emerged as a therapeutic modality to eliminate previously undruggable proteins by repurposing the cell’s endogenous protein degradation machinery. However, the susceptibility of proteins for targeting by TPD approaches, termed “degradability”, is largely unknown. Here, we developed a machine learning model, model-free analysis of protein degradability (MAPD), to predict degradability from features intrinsic to protein targets. MAPD shows accurate performance in predicting kinases that are degradable by TPD compounds [with an area under the precision–recall curve (AUPRC) of 0.759 and an area under the receiver operating characteristic curve (AUROC) of 0.775] and is likely generalizable to independent non-kinase proteins. We found five features with statistical significance to achieve optimal prediction, with ubiquitination potential being the most predictive. By structural modeling, we found that E2-accessible ubiquitination sites, but not lysine residues in general, are particularly associated with kinase degradability. Finally, we extended MAPD predictions to the entire proteome to find 964 disease-causing proteins (including proteins encoded by 278 cancer genes) that may be tractable to TPD drug development.
Genomic innovation and regulatory rewiring during evolution of the cotton genus Gossypium
Authors: Maojun Wang, Jianying Li, Zhengyang Qi, Yuexuan Long, Liuling Pei, Xianhui Huang, Corrinne E. Grover, Xiongming Du, Chunjiao Xia, Pengcheng Wang, Zhenping Liu, Jiaqi You, Xuehan Tian, Yizan Ma, Ruipeng Wang, Xinyuan Chen, Xin He, David D. Fang, Yuqiang Sun, Lili Tu, Shuangxia Jin, Longfu Zhu, Jonathan F. Wendel, Xianlong Zhang
Journal: Nature Genetics (2022)
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants
Authors: Krishna G. Aragam, Tao Jiang, Anuj Goel, Stavroula Kanoni, Brooke N. Wolford, Deepak S. Atri, Elle M. Weeks, Minxian Wang, George Hindy, Wei Zhou, Christopher Grace, Carolina Roselli, Nicholas A. Marston, Frederick K. Kamanu, Ida Surakka, Loreto Muñoz Venegas, Paul Sherliker, Satoshi Koyama, Kazuyoshi Ishigaki, Bjørn O. Åsvold, Michael R. Brown, Ben Brumpton, Paul S. de Vries, Olga Giannakopoulou, Panagiota Giardoglou, Daniel F. Gudbjartsson, Ulrich Güldener, Syed M. Ijlal Haider, Anna Helgadottir, Maysson Ibrahim, Adnan Kastrati, Thorsten Kessler, Theodosios Kyriakou, Tomasz Konopka, Ling Li, Lijiang Ma, Thomas Meitinger, Sören Mucha, Matthias Munz, Federico Murgia, Jonas B. Nielsen, Markus M. Nöthen, Shichao Pang, Tobias Reinberger, Gavin Schnitzler, Damian Smedley, Gudmar Thorleifsson, Moritz von Scheidt, Jacob C. Ulirsch, John Danesh, David O. Arnar, Noël P. Burtt, Maria C. Costanzo, Jason Flannick, Kaoru Ito, Dong-Keun Jang, Yoichiro Kamatani, Amit V. Khera, Issei Komuro, Iftikhar J. Kullo, Luca A. Lotta, Christopher P. Nelson, Robert Roberts, Gudmundur Thorgeirsson, Unnur Thorsteinsdottir, Thomas R. Webb, Aris Baras, Johan L. M. Björkegren, Eric Boerwinkle, George Dedoussis, Hilma Holm, Kristian Hveem, Olle Melander, Alanna C. Morrison, Marju Orho-Melander, Loukianos S. Rallidis, Arno Ruusalepp, Marc S. Sabatine, Kari Stefansson, Pierre Zalloua, Patrick T. Ellinor, Martin Farrall, John Danesh, Christian T. Ruff, Hilary K. Finucane, Jemma C. Hopewell, Robert Clarke, Rajat M. Gupta, Jeanette Erdmann, Nilesh J. Samani, Heribert Schunkert, Hugh Watkins, Cristen J. Willer, Panos Deloukas, Sekar Kathiresan, Adam S. Butterworth, Paul S. de Vries, Moritz von Scheidt
Journal: Nature Genetics (2022)

The discovery of genetic loci associated with complex diseases has outpaced the elucidation of mechanisms of disease pathogenesis. Here we conducted a genome-wide association study (GWAS) for coronary artery disease (CAD) comprising 181,522 cases among 1,165,690 participants of predominantly European ancestry. We detected 241 associations, including 30 new loci. Cross-ancestry meta-analysis with a Japanese GWAS yielded 38 additional new loci. We prioritized likely causal variants using functionally informed fine-mapping, yielding 42 associations with less than five variants in the 95% credible set. Similarity-based clustering suggested roles for early developmental processes, cell cycle signaling and vascular cell migration and proliferation in the pathogenesis of CAD. We prioritized 220 candidate causal genes, combining eight complementary approaches, including 123 supported by three or more approaches. Using CRISPR-Cas9, we experimentally validated the effect of an enhancer in MYO9B, which appears to mediate CAD risk by regulating vascular cell motility. Our analysis identifies and systematically characterizes >250 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD.